🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #AACR24, Alex Soupir, PhD, (Alex Soupir) presents on the genomic landscape and estimation of immune infiltration of soft tissue sarcoma histology subtypes from the ORIEN network. Key findings: 1️⃣ORIEN provides an extensive number and variety of sarcoma histological subtypes

Further understanding the tumor environment to shed light on differences in histological subtypes and patient survival. Wonderful study Oscar Ospina

At #ASCO24, Andrew Brohl, MD (Andrew Brohl) discusses a personalized vaccine that shows promise in Merkel cell carcinoma. #MoffittASCO24 bit.ly/3V4UM7J

At #ASCO24, Andrew Brohl, MD (Andrew Brohl) discusses the latest in Merkel cell carcinoma & cutaneous squamous cell carcinoma treatments. #MoffittASCO24 Learn more: bit.ly/4bDnZhd ASCO

Andrew Brohl, MD (Andrew Brohl) joins us to discuss the durability of immune checkpoint inhibitor response following treatment discontinuation in advanced Merkel cell carcinoma at #ASCO24. #MoffittASCO24

During #ASCO24, Andrew Brohl, MD (Andrew Brohl) joined Patrick Hwu, MD (Dr. Patrick Hwu) to discuss the latest in Merkel cell carcinoma. #MoffittASCO24

During #ASCO24, Andrew Brohl, MD (Andrew Brohl) joined Patrick Hwu, MD (Dr. Patrick Hwu) to discuss the latest in Merkel cell carcinoma. #MoffittASCO24

New #JITC article: Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma bit.ly/3yWwxSk Vernon K Sondak MD Nikhil Khushalani Andrew Brohl

Our #sarcoma medical oncology leader Mihaela Druta gave an outstanding talk today on the translational endpoints from the SPEARHEAD-1 trial. Moffitt Cancer Center Adaptimmune #SITC2024 #MoffittSITC24

LIVE from #SITC24, Marian Smallin (Marian Smallin) joins us to discuss how the chromosome 19 microRNA cluster promotes TIL-based immune evasion in #melanoma. #MoffittSITC24 Learn more ➡️ bit.ly/48Ciu1q Society for Immunotherapy of Cancer

🚨Breaking Science from #ASCO25. Kenneth Tsai, MD, PhD, (Kenneth Y. Tsai) joined us to discuss new data from the C-POST trial on adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma. Details ⬇️ Read more: meetings.asco.org/abstracts-pres… #MoffittASCO25 ASCO

From #ASCO25: Andrew Brohl, MD (Andrew Brohl) presents a randomized trial evaluating IFx-Hu2.0 plus pembrolizumab as first-line therapy in advanced Merkel cell carcinoma. The study explores a novel innate immune agonist to boost checkpoint inhibitor response. #MoffittASCO25

Join Andrew Brohl, MD, (Andrew Brohl) tomorrow at #ASCO25 as he discusses a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma. Read more: meetings.asco.org/2025-asco-annu… #MoffittASCO25 ASCO

Now in the #melanoma rapid oral presentation at #ASCO25: Moffitt’s own Andrew Brohl, MDA (Andrew Brohl) presents phase II results on neoadjuvant lenvatinib + pembrolizumab in resectable clinical stage I–IV Merkel cell carcinoma. Key conclusions: ➡️ Promising efficacy: 57.7%

LIVE from #ASCO25: Andrew Brohl, MD, (Andrew Brohl) shares promising results from a phase II study neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma. Key findings: • Pembrolizumab plus Lenvatinib had encouraging efficacy as neoadjuvant therapy for resectable

x.com/i/article/1928…

Today at #ASCO25, Andrew Brohl, MD, (Andrew Brohl) discusses an immunotherapy combo showing promise as a pre-surgical treatment for Merkel cell carcinoma. Read more: moffitt.org/endeavor/archi… #MoffittASCO25 ASCO

Enjoying #ASCO25 so far! Congrats to Andrew Brohl on his oral presentation on neoadjuvant lenvatinib + pembrolizumab in MCC. Results highlight the potential for new combination therapies and biomarkers. We also filmed a chat about exciting sarcoma breakthroughs! #MoffittASCO25

At #ASCO25, Mihaela Druta, MD, (Mihaela Druta) and Andrew Brohl, MD, (Andrew Brohl) discuss emerging science on Merkel cell carcinoma and sarcoma. #MoffittASCO25

🎤Please check out my new publication! url.us.m.mimecastprotect.com/s/B6VUCERKrkh3…